In contrast, our current study showed that there was a significantly better PFS in colorectal cancers possessing all wild-type copies of KRAS, NRAS, and BRAF than in colorectal cancers with at least one mutation of KRAS, NRAS, and BRAF, although no significant differences in OS were observed between them (data not shown). The gene discussed is BRAF; the disease is colorectal cancer.